2023 MAR 25 John Campbell TGA document revelations regarding a TGA Nonclinical Evaluation Report Part 2 of 4
TGA REDACTED CONTENT: Why the Concealment of any TECHNICAL DATA
John Campbell walks us through significant revelations found in the TGA Nonclinical Evaluation Report
TGA released for public viewing after persistent pressure from the FOI requestor. However, redacted some of the content WHY Conceal Technical Data.
UAP National Director Craig Kelly said1 regarding the TGA Nonclinical Evaluation Report: “It confirms that the TGA knew back in Jan 2021 that the lipid nanoparticles (and the mRNA) didn’t stay in the inject site, but spread throughout the entire body including the brain, the liver and female ovaries.”
Kelly continued2 ”This should have raised red flags everywhere, especially when there was zero data of what the medium- & long-term adverse effects that this would cause.”
TGA DELIBERATELY CONCEALED “CRITICAL DATA” REQUIRED TO MAKE INFORMED CONSENTS
“How could the TGA possibly assert "safe & effective" in humans when the data showed it wasn’t even safe in rats!” said3 UAP National Director
Kelly went on to say4 : “Yet the TGA allowed these experimental injections to be approved with the intention that this substance would injected; into every Australian - and the TGA KEPT QUIET about the fact that mRNA would spread through the entire body.” “This Destroyed the Concept of Informed Consent".
MAJOR CRIMES INVESTIGATION of TGA REQUIRED NOW
In closing his remarks Kelly said5 : “THE AUSTRALIAN FEDERAL POLICE should be down at the TGA this morning seizing their computers and phones and starting to take people into custody.” “No wonder the TGA desperately tried to prevent this document being released under Freedom of Information.”
DR. JOHN CAMPBELLS NOTES
provided with the Video regarding the TGA (Therapeutic Goods administration) Nonclinical Evaluation Report6 (January 2021)
Page 4 “Almost similar microscopic lung inflammation was observed in both challenged control and immunised animals (macaques) after the peak of infection (Days 7/8)” Challenged with infection, (unvaccinated) control animals Almost similar microscopic lung inflammation Challenged with infection, immunized (vaccinated) animals Almost similar microscopic lung inflammation Page 4 “There are no distribution and degradation data on the S antigen-encoding mRNA.”
A new therapy that uses an intra-cellular pathway to use intracellular ribosomes We know from page 45 the lipid nanoparticles are systemically distributed, But the spike protein that the RNA produces, distribution not tested No data on how long the spike protein persists Page 5 “Antibodies and T cells in monkeys declined quickly over 5 weeks after the second dose of BNT162b2 (V9), raising concerns over long term immunity” Page 6 – A few unknowns were identified by the TGA “Short term protection studies, lack of pharmacokinetic data for the S antigen-encoding mRNA (BNT162b2 V9), suboptimal dosing interval in the repeat dose study, lack of repeat dose toxicity studies in a second species, and genotoxicity studies with the novel excipients, (a substance formulated alongside the active ingredients) and lack of studies investigating potential for autoimmune diseases were noted.”
Page 6 – Unknown go on “Long term immunity, vaccine induced autoimmune diseases were not studied in the nonclinical program” Page 8 “BNT162b2 immunisation also induced proinflammatory cytokines such as GM-CSF, TNF-α, IL-6 and IL-18, in addition to IFN-γ, in splenocytes.”
Page 9 “One study found that among people who had recovered from COVID-19, 100% had S protein-specific CD4+ T cells in the circulation and 70% had S protein-specific CD8+ T cells in the circulation.
PFIZER DOCUMENT SUBMITTED TO THE TGA:
Nonclinical Evaluation Report.
Generic name: BNT162b2 [mRNA] COVID-19 vaccine
Trade name: COMIRNATY
Submission No: PM-2020-05461-1-2
Sponsor/Author: Pfizer Australia Pty Ltd
Date submitted: January 2021
Pages: 58 | Filesize: 2.52 MB
Download PDF Copy: https://t.me/FOURCMVAULT/349
Video Original Source: WATCH HERE